Innovation & intellectual property · 10/11/2009Updated: 10/17/2026 · 1 min read
U.S. Patent Office Extends Mifamurtide Patent Term for Third Time
Summary
The United States Patent and Trademark Office has granted a third one-year interim extension to the term of U.S. Patent No. 4,971,802, which covers Mifamurtide, a cancer treatment drug.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →